摘要
由于诊疗手段的不断改进,霍奇金淋巴瘤已成为治愈率较高的恶性肿瘤.但随着患者生存期的延长,治疗的远期不良反应越来越受到临床医生的关注.因此,根据疾病分期和危险因素对患者实施个体化治疗是目前霍奇金淋巴瘤的研究热点.本文综述了近年来早期经典型霍奇金淋巴瘤在个体化治疗方面的研究进展.
Much progress has been made in the diagnosis and treatment of Hodgkin's lymphoma, which has become a highly curable malignancy.However, prolonged survival makes clinicians pay more attention to long-term toxicities of treatment.Consequently, individualized treatment based on disease stage and risk factors is a research hotspot at present.This article reviews recent advances in the individualized treatment of early-stage classical Hodgkin's lymphoma.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2017年第5期578-581,共4页
Chinese Journal of Radiation Oncology